Cytokinetics (CYTK) Has $2-$4 Upside on Upcoming CK-274 Data Readout, None of It Priced In, Data as Early as Next Week - Mizuho
Tweet Send to a Friend
(Updated - January 14, 2022 11:32 AM EST)Mizuho Securities analyst Salim Syed reiterated a Buy rating and $54.00 price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
